US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...

Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...

(Alliance News) - GSK PLC said on Monday that the US Food & Drug Administration accepted a biologics license application for its Blenrep combinations for the treatment of relapsed and refractory ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review a Biologics License Application, BLA, for Blenrep in combinations with bortezomib plus dexamethasone and ...

Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease ...

在抗肿瘤药物研发的复杂舞台上，Blenrep的故事宛如一出跌宕起伏的戏剧。曾几何时，这款靶向BCMA的抗体药物被视为GSK重返癌症领域的利器，然而，市场的残酷和临床试验的不确定性让它经历了一波三折的命运。对于许多人来说，Blenrep的退市似乎意味着它的终章，但就在GSK即将放弃时，新的希望又重新燃起。在临床试验DREAMM-7的中期分析显示出积极结果时，这款产品又重新回到了公众的视野中。

第15届医博会期间，同写意生物医药新基建链盟将举办ADC专场，邀请抗体/ADC研发端、生产端和供应链端的企业负责人与会深度交流，帮助行业优化和提升生物药创新生态链。

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...

Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...